RATINGS CHANGES

Amazon (AMZN) - Get Report was initiated with an overweight rating at Barclays. The company has the best growth potential among top internet names, Barclays said. 

Chemours (CC) - Get Report was upgraded to buy at Jefferies. $48 price target. TiO2 and fluoropolymers could drive further upside, Jefferies said. 

Capital One (COF) - Get Report was upgraded to buy from neutral at Nomura. $105 price target. The company's subprime bet should now pay off, Nomura said. 

Dunkin' Brands (DNKN) - Get Report was downgraded to sell from neutral at Goldman Sachs. $47 price target. The company is trading at a peak valuation and is facing growth headwinds, Goldman said. 

Darden (DRI) - Get Report was downgraded to neutral from buy at BTIG. The valuation is less attractive, as the stock is trading at 19 times expected 2018 earnings, BTIG said.

Facebook (FB) - Get Report was initiated with an overweight rating at Barclays. $154 price target. The company is the best pure play on mobile advertising, Barclays said. 

F5 Networks (FFIV) - Get Report was downgraded to sell from hold at Deutsche Bank. $100 price target. Earnings estimates were also cut, as growth should decelerate into 2018, Deutsche said. 

Alphabet (GOOGL) - Get Report (GOOG) - Get Report was initiated with an overweight rating at Barclays. $1,065 price target. The company can generate 20% annual sales and earnings growth for the next few years, Barclays said. 

Morgan Stanley (MS) - Get Report was upgraded to buy from hold at Deutsche Bank. $47 price target. Stock is down 10%, but the analyst is optimistic about capital markets and an improvement in trading, Deutsche said. 

Nabors Industries (NBR) - Get Report was downgraded to sell at TheStreet Ratings. You can view the full analysis from the report here: NBR.

Target (TGT) - Get Report was downgraded to hold at TheStreet Ratings. You can view the full analysis from the report here: TGT.

Twitter (TWTR) - Get Report was initiated with an underweight rating at Barclays. $14 price target. Revenue growth has turned negative and the stock is trading at 110 times expected 2018 EBITDA, Barclays said. 

Vertex (VRTX) - Get Report was upgraded to outperform from market perform at BMO Capital. $128 price target. Positive Phase III data suggests that triple combination treatment now has a 65% chance of success, BMO said. 

This article was written by a staff member of TheStreet.